BioWorld

July 7, 2004

Chiron Takes Over Sagres, Gains Wealth' Of Targets

Looking to boost the value of its recent cancer deal with XOMA Ltd., Chiron Corp. is acquiring Sagres Discovery Inc. for undisclosed terms. (BioWorld Today) Read More

FDA Clears NeutroSpec, Gives Palatin First Product Approval

Despite Pressure, FDA Backing Authorized Generic' Marketing

Novo Taking More Proteins In Deal With ZymoGenetics

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 4, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...